http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2013129990-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L2430-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2830-46 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-71 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-85 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0051 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-179 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85 |
| filingDate | 2011-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2013129990-A |
| titleOfInvention | CELL LINES THAT SECRET THE STRUCTURES OF ANTI-ANGIOGENIC ANTIBODY-FRAME AND SOLUBLE RECEPTORS AND THEIR APPLICATION |
| abstract | 1. A cell line containing ARPE-19 cells genetically engineered to produce a therapeutically effective amount of one or more anti-angiogenic antibody-scaffold constructs or anti-angiogenic molecules, wherein said one or more anti-angiogenic antibody-scaffold constructs or anti-angiogenic molecules are introduced into cells ARPE-19 using an iterative transfection method, wherein said iterative transfection comprises one transfection, two transfection, or three transfections. 2. A cell line according to claim 1, wherein said cell line produces one or more anti-angiogenic antibody-scaffold constructs or anti-angiogenic molecules in an amount of 10,000-30000 ng / day / 10 cells, if one transfection is one transfection. 3. A cell line according to claim 2, wherein said cell line produces one or more anti-angiogenic antibody-scaffold constructs or anti-angiogenic molecules in an amount of 15,000 ng / day / 10 cells. A cell line according to claim 1, wherein said cell line produces one or more anti-angiogenic antibody-scaffold constructs or anti-angiogenic molecules in an amount of 30000-50000 ng / day / 10 cells, if two transfections are iterative transfection. The cell line according to claim 4, wherein said cell line produces one or more anti-angiogenic antibody-scaffold constructs or anti-angiogenic molecules in an amount of 35,000 ng / day / 10 cells. A cell line according to claim 1, wherein said cell line produces one or more anti-angiogenic antibody-framework constructs or anti-angiogenic molecules in an amount of 50,000-75,000 ng / day / 10 cells, if iterative transfection is tr |
| priorityDate | 2010-12-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.